Gapping up
In reaction to earnings/guidance:
- LPSN +21.6% (also CEO steps down), MQ +20.4% (also signs extension SQ to continue powering its Cash App card), CELH +16.8%, AZTA +15.7%, AXON +15.3%, TOST +15.2%, PENN +14.1%, BOOM +13.8%, ARRY +13.6%, RPD +11.8%, MRTX +10.6% (also CEO steps down; also files $250 mln common stock offering), VUZI +10.6%, SOUN +10.6%, PETQ +8.6%, AMPL +7.7%, IONS +7.5%, RKLB +7.1% (also signs a block buy deal for five Electron launches with BlackSky), DUOL +6.6%, TWLO +6.6%, AKAM +6.3%, ARHS +6.1%, TH +6.1%, VCYT +6%, ANIP +5.5%, WRBY +5.4%, CPNG +5%, CTOS +5%, CDRE +5%, VVV +5%, LFST +4.8%, FLYW +4.6% (also CFO to step down in 2024), MEG +4.4%, LGND +4.4%, DNLI +4.3%, BW +4%, EVRI +4%, BLNK +3.9%, HALO +3.9%, BIRD +3.9%, FNF +3.9%, TBLA +3.9%, OSCR +3.8% (also names new CFO), PRA +3.6%, CDNA +3.3%, CRL +3.3%, SII +3.3%, TTWO +3%, SKIN +2.9%, ESTA +2.8%, HNST +2.8%, DHT +2.7%, QGEN +2.6%, FNV +2.6%, SSYS +2.5%, LAZR +2.4%, KIND +2.4%, HMC +2.4%, MODN +2.2%, TWNK +2.1%, ACCO +2% (also CEO to retire, names new CEO), GO +2%, ESE +2%, RVMD +2%, DCPH +2%, AVDL +2%, ATMU +2%, SLF +1.9%, RXT +1.8%, BROS +1.8% (also names new CEO), HYLN +1.8%, INSW +1.8%, SHCR +1.6%, VERX +1.5%, CMP +1.3%, ASX +1.3% (July revs), XMTR +1.2%, PODD +1.1%, IPAR +1%
Other news:
- CTG +27.1% (Cegeka will acquire CTG for $10.50/share in cash)
- SCPL +15% (LNW to acquire remaining stake in SCPL it does not already own)
- PENN +14% (enters into online sports betting agreement with ESPN)
- SKLZ +5% (CEO bought 75000 shares)
- PGEN +4.3% (FDA has agreed that the ongoing Phase 1/2 single arm study of the first-in-class investigational PRGN-2012 AdenoVerse immunotherapy for the treatment of recurrent respiratory papillomatosis will serve as pivotal for the purpose of filing an accelerated approval request for licensure)
- ATAI +2.3% (announces results from Phase 1 study of PCN-101)
- ICVX +2% (provides update from its Phase 1b extension trial of IVX-121)
- MCRB +1.4% (files $300 mln mixed shelf securities offering)
- XFOR +1.2% (names new CMO)
Analyst comments:
- EQNR +3.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
